Comment on

• Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.

  Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Hainsworth JD, et al. J Clin Oncol. 2005 Feb 20;23(6):1088-95. doi: 10.1200/JCO.2005.12.191. Epub 2005 Jan 18. J Clin Oncol. 2005. PMID: 15657401 Clinical Trial.
• Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders.

  Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Gordan LN, et al. J Clin Oncol. 2005 Feb 20;23(6):1096-102. doi: 10.1200/JCO.2005.12.171. Epub 2005 Jan 18. J Clin Oncol. 2005. PMID: 15657402 Clinical Trial.
• Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group.

  Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA. Witzig TE, et al. J Clin Oncol. 2005 Feb 20;23(6):1103-8. doi: 10.1200/JCO.2005.12.052. Epub 2005 Jan 18. J Clin Oncol. 2005. PMID: 15657404 Clinical Trial.